ea0063oc13.4 | Anterior and Posterior pituitary 2 | ECE2019
Bentz Damholt Birgitte
, Dahl Bendtsen Mette
, Hollensen Christian
, Hojby Rasmussen Michael
Background: Somapacitan is a reversible albumin-binding growth hormone (GH) derivative developed for once-weekly administration. Non-covalent binding to endogenous albumin delays somapacitan elimination, prolonging its half-life and duration of action. Somapacitan is not cleared by a specific organ, but impaired hepatic function may affect its pharmacokinetics. We report data from an open-label, parallel group, phase I trial (NCT03212131) investigating the pharmacokinetic and ...